A 68930

D-1 dopamine receptor agonist

Also Known As:

1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran; 5,6-dihydroxy-3-phenyl-1-aminomethylisochroman; A 70108; A 70360; A-68930; A-70108; A-70360; A68930; A70108; A70360; 1H-2-benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-phenyl-, (1R,3S)-

Networked: 16 relevant articles (7 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromans: 3
        A 68930: 16
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromans: 3
        A 68930: 16

Experts

1.	Cheng, Zhao-Yan: 2 articles (10/2021 - 11/2020)
2.	He, Ling: 2 articles (10/2021 - 11/2020)
3.	Hu, Yu-Hui: 2 articles (10/2021 - 11/2020)
4.	Wang, Chen: 2 articles (10/2021 - 11/2020)
5.	Xia, Qing-Peng: 2 articles (10/2021 - 11/2020)
6.	Chen, Wu-Fu: 2 articles (03/2007 - 11/2004)
7.	Huang, Li-Tung: 2 articles (03/2007 - 11/2004)
8.	Yang, Chin-Hwa: 2 articles (03/2007 - 11/2004)
9.	Yang, San-Nan: 2 articles (03/2007 - 11/2004)
10.	Jin, Yuxuan: 1 article (01/2021)

Related Diseases

1.	Spinal Cord Injuries (Spinal Cord Injury) 11/01/2016 - "The study aimed to investigate the therapeutic efficacy and molecular mechanisms of A-68930 in a rat model of spinal cord injury (SCI)-induced acute lung injury (ALI). " 03/01/2016 - "The aim of this study was to investigate the therapeutic efficacy and molecular mechanisms of dopamine D1 receptor agonist A-68930 in spinal cord injury (SCI) rats. " 11/01/2016 - "Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury." 03/01/2016 - "Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation, Controls Inflammation, and Alleviates Histopathology in a Rat Model of Spinal Cord Injury."
2.	Hypoxia (Hypoxemia) 03/01/2007 - "In addition, activation of the D1/D5R via A68930 (a selective, CNS-permeable agonist of D1/D5Rs) administration (2 mg/kg/day, P17-23 inclusively) markedly attenuated the hypoxia-induced deleterious effects, suggesting an effective therapeutic efficacy for A68930. " 11/16/2004 - "Impaired SynGAP expression and long-term spatial learning and memory in hippocampal CA1 area from rats previously exposed to perinatal hypoxia-induced insults: beneficial effects of A68930." 11/16/2004 - "We also evaluated the therapeutic efficacy of A68930, a selective agonist of dopamine D1/D5 receptors, on perinatal hypoxia insults. "
3.	Cognitive Dysfunction 11/01/2020 - "Here we showed that intraperitoneal injection of A-68930 significantly ameliorated Aβ1-42-induced cognitive dysfunction in mice. " 10/01/2021 - "This study sought to test whether the selective DRD1 agonist A-68930 could improve streptozotocin (STZ)-induced cognitive impairment in mice. " 11/01/2020 - "Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice."
4.	Acute Lung Injury 11/01/2016 - "The study aimed to investigate the therapeutic efficacy and molecular mechanisms of A-68930 in a rat model of spinal cord injury (SCI)-induced acute lung injury (ALI). " 11/01/2016 - "Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury."
5.	Inflammation (Inflammations) 01/04/2018 - "DRD1 activation by A68930 improves neurological outcome through inhibition of NLRP3-mediated inflammation in ICH mice." 07/01/2020 - "In summary, our results demonstrated that activation of DRD1 by A68930 inhibited renal and systematic inflammation, and improved kidney function in I/R induced AKI model, which was probably related to the inhibition of the NLRP3 inflammasome activation." 03/01/2016 - "Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation, Controls Inflammation, and Alleviates Histopathology in a Rat Model of Spinal Cord Injury."

Related Drugs and Biologics

1.	Dopamine D1 Receptors (Dopamine D1 Receptor)
2.	Dopamine (Intropin)
3.	Inflammasomes
4.	Streptozocin (Streptozotocin)
5.	Quinpirole
6.	Clozapine (Clozaril)
7.	SCH 23390
8.	5-HT1A Serotonin Receptor
9.	Muscarinic M1 Receptor
10.	Small Interfering RNA (siRNA)

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Intravenous Infusions